Drugs / MDX-1342
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00593944 | Aug 2008 → May 2010 | B-cell chronic lymphocytic leukemia | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00639834 | Feb 2008 → Jun 2010 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDX-1342 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00593944 ↗ |
| Action | Inhibit | “Therefore, it is theorized that MDX-1342 will block activation of B cell stimulation, decreasing the number of cancerous B cell clones.” NCT00593944 ↗ |
| Modality | Monoclonal antibody | “MDX-1342, a fully human monoclonal antibody, has demonstrated to specifically bind to human CD19 antigen with high affinity.” NCT00593944 ↗ |
| Route | Intravenous | “MDX-1342 is given as a 90 minute i.v. infusion.” NCT00593944 ↗ |
| Target | CD19 | “MDX-1342, a fully human monoclonal antibody, has demonstrated to specifically bind to human CD19 antigen with high affinity.” NCT00593944 ↗ |